Skip to main content
SpringerLink
Log in

Clinical utility of antigen carbohydrate 125 in heart failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

In recent years, there has been a proliferation of new biomarkers with potential prognostic implication in heart failure (HF). Nevertheless, most of them do not fulfill the required criteria for being used in daily clinical practice. Tumor marker antigen carbohydrate 125 (CA125), a glycoprotein widely used for ovarian cancer monitoring, is synthesized by epithelial serous cells in response to fluid accumulation and/or cytokine stimuli. This glycoprotein has been emerged as a potential biomarker in HF. Plasma CA125 correlates with clinical, hemodynamic, and echocardiographic parameters related to the severity of the disease. High levels have shown to be present in the majority of acutely decompensated patients, and in this setting, it has shown to be independently related to mortality or subsequent admission for acute HF. In addition, certain characteristics such as wide availability and the close correlation between plasma changes with disease severity and clinical outcomes have increased the interest of researchers about the potential of this glycoprotein for monitoring and guiding therapy in HF. In this article, we have reviewed the available evidence supporting the potential role of CA125 as a biomarker in HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Richards AM (2009) What we may expect from biomarkers in Heart Failure. Heart Fail Clin 5:463–470

    Article  PubMed  Google Scholar 

  2. Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159

    Article  CAS  PubMed  Google Scholar 

  3. Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952

    Article  PubMed  Google Scholar 

  4. Richards AM (2010) New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 63:635–639

    Article  PubMed  Google Scholar 

  5. Palazzuoli A, Masson S, Ronco C, Maisel A (2013) Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. doi:10.1007/s10741-013-9391-x

  6. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47:263–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL (1986) Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143–6148

    CAS  PubMed  Google Scholar 

  9. Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765–769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150–154

    Article  CAS  PubMed  Google Scholar 

  11. Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS (2003) Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 278:28619–28634

    Article  PubMed  Google Scholar 

  12. Murdoch WJ, Van Kirk EA, Smedts AM (2006) Complement-inhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 236:54–57

    Article  CAS  PubMed  Google Scholar 

  13. Yoshimura M, Ihara Y, Ohnishi A, Ijuhin N, Nishiura T, Kanakura Y, Matsuzawa Y, Taniguchi N (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res 56:412–418

    CAS  PubMed  Google Scholar 

  14. Núñez J, Miñana G, González M, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Chorro FJ, Llàcer A, Miguel A (2011) Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? Int J Cardiol 146:473–474

    Article  PubMed  Google Scholar 

  15. Núñez J, Miñana G, Núñez E, Sanchis J (2011) Antigen carbohydrate 125 in heart failure: a promising clinical tool. Int J Cardiol 150:369–370

    Article  PubMed  Google Scholar 

  16. Ege MR, Zorlu A, Yılmaz MB (2011) CA-125 and heart failure. Int J Cardiol 147:453–454

    Article  PubMed  Google Scholar 

  17. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172–175

    Article  CAS  PubMed  Google Scholar 

  18. Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7:840–843

    Article  CAS  PubMed  Google Scholar 

  19. Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Hum Reprod 15:1261–1265

    Article  CAS  PubMed  Google Scholar 

  20. Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K (1993) Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 57:489–494

    Article  CAS  PubMed  Google Scholar 

  21. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8:270–274

    Article  CAS  PubMed  Google Scholar 

  22. Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A (2010) Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752–1763

    Article  PubMed  Google Scholar 

  23. Topatan B, Basaran A (2010) CA-125 and heart failure: déjà vu or “still to be seen”. Int J Cardiol 145:626–629

    Article  PubMed  Google Scholar 

  24. Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H (2012) New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 79:381–383

    Article  CAS  PubMed  Google Scholar 

  25. Miñana G, Núñez J, Sanchis J, Bodí V, Núñez E, Llàcer A (2010) CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 145:547–548

    Article  PubMed  Google Scholar 

  26. Hamdy NM, Basaran A (2011) Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 17:CR174–CR179

    Article  PubMed  Google Scholar 

  27. Núñez J, González M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau P, Merlos P, Llàcer A, Miguel A (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548

    Article  PubMed  Google Scholar 

  28. Colombo PC, Jorde UP (2010) The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 63:5–8

    Article  Google Scholar 

  29. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12:423–433

    Article  PubMed  Google Scholar 

  30. Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N (2010) Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 12:995–1001

    Article  CAS  PubMed  Google Scholar 

  31. Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935–2012

    Article  CAS  PubMed  Google Scholar 

  32. Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A (2007) Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93:716–721

    Article  PubMed  PubMed Central  Google Scholar 

  33. D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41:1805–1811

    Article  PubMed  Google Scholar 

  34. Faggiano P, D’Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L (2005) Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7:57–61

    Article  CAS  PubMed  Google Scholar 

  35. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7:199–203

    Article  CAS  PubMed  Google Scholar 

  36. Duman D, Palit F, Simsek E, Bilgehan K (2008) Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 10:556–559

    Article  CAS  PubMed  Google Scholar 

  37. Nägele H, Bahlo M, Klapdor R, Rödiger W (1999) Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 19:2531–2534

    PubMed  Google Scholar 

  38. Hung CL, Hung TC, Liu CC, Wu YJ, Kuo JY, Hou CJ, Yeh HI (2012) Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 110:993–1000

    Article  CAS  PubMed  Google Scholar 

  39. Yilmaz MB, Zorlu A, Tandogan I (2011) Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 149:80–82

    Article  PubMed  Google Scholar 

  40. Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W (1999) CA 125 and its relation to cardiac function. Am Heart J 137:1044–1049

    Article  PubMed  Google Scholar 

  41. Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, Kandis H (2012) Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 39:30–35

    PubMed  PubMed Central  Google Scholar 

  42. Mansour IN, Napan S, Tarek Alahdab M, Stamos TD (2010) Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 16:15–20

    Article  CAS  PubMed  Google Scholar 

  43. Vizzardi E, D’Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L (2012) Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 18:68–73

    Article  CAS  PubMed  Google Scholar 

  44. Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliveira L, Providência LA (2010) Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 140:115–118

    Article  PubMed  Google Scholar 

  45. Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406–412

    Article  PubMed  Google Scholar 

  46. Varol E, Yücel H, Arslan A, Ozaydın M, Erdoğan D, Doğan A (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40:309–315

    Article  PubMed  Google Scholar 

  47. Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22:30–33

    Article  PubMed  Google Scholar 

  48. Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ, Gol G, Kahveci G, Esen O, Esen AM, Turkmen M (2012) Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 18:144–150

    Article  CAS  PubMed  Google Scholar 

  49. Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, Palau P, Bertomeu-González V, Carratalá A, Mainar L, Chorro FJ, Llàcer A (2012) CA125 and BNP serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 159:21–28

    Article  PubMed  Google Scholar 

  50. Miñana Escrivá G, Núñez J, Sanchis J, Bodi V, Núñez E, Chorro FJ, Llàcer A (2012) Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 139:479–486

    Article  Google Scholar 

  51. Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodi V, Riegger G, Schmid C, Hilker M, Hengstenberg C (2013) Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 6:487–496

    Article  PubMed  Google Scholar 

  52. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003

    Article  Google Scholar 

  53. Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367–377

    Article  PubMed  Google Scholar 

  54. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695–1707

    CAS  PubMed  Google Scholar 

  55. O’Donoghue M, Braunwald E (2010) Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7:13–20

    Article  PubMed  Google Scholar 

  56. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261

    Article  CAS  PubMed  Google Scholar 

  57. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231–1239

    Article  PubMed  Google Scholar 

  58. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation 120:2188–2196

    Article  CAS  PubMed  Google Scholar 

  59. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, PEARL Study Investigators (2013) Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77:917–925

    Article  CAS  PubMed  Google Scholar 

  60. Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, Miñana G, Palau P, Fácila L, Chorro FJ, Bertomeu-Martínez V, Llàcer A (2011) Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure. Rev Esp Cardiol 64:1100–1108

    Article  Google Scholar 

  61. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869

    Article  CAS  PubMed  Google Scholar 

  62. Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS (2008) Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13:211–225

    Article  CAS  PubMed  Google Scholar 

  63. Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. Int J Cardiol 112:234–242

    Article  PubMed  Google Scholar 

  64. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (corona): a retrospective analysis. Circulation 120:2188–2196

    Article  CAS  PubMed  Google Scholar 

  65. Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62

    Article  PubMed  PubMed Central  Google Scholar 

  66. Eshaghian S, Horwich TB, Fonarow GC (2009) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764

    Article  Google Scholar 

  67. Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439

    Article  PubMed  PubMed Central  Google Scholar 

  68. Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P, Sanchis J (2012) Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 14:974–984

    Article  PubMed  PubMed Central  Google Scholar 

  69. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596

    Article  PubMed  PubMed Central  Google Scholar 

  70. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233–2241

    Article  PubMed  Google Scholar 

  71. van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58:127–138

    Article  PubMed  Google Scholar 

  72. Schmitter D, Cotter G, Voors AA (2013) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev. doi:10.1007/s10741-013-9396-5

  73. Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. doi:10.1016/j.bbadis.2012.12.014

  74. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23–35

    Article  CAS  PubMed  Google Scholar 

  75. Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Cardiac Fail 15:256–266

    Article  Google Scholar 

  76. Sherwi N, Merali S, Wong K (2012) Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 8:885–894

    Article  CAS  PubMed  Google Scholar 

  77. Bhardwaj A, Januzzi JL Jr (2010) ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10:459–464

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a grants from Instituto de Salud Carlos III, Red de Investigación Cardiovascular, Programa 7 (RD12/0042/0010) FEDER, PI11/02323 and Prometeo/2013/007.

Conflict of interest

Drs. Julio Núñez, Gema Miñana, Eduardo Núñez, Francisco J. Chorro, Vicent Bodí, and Juan Sanchis have no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de Valencia, Avda. Blasco Ibáñez 17, 46010, Valencia, Spain

    Julio Núñez, Eduardo Núñez, Francisco J. Chorro, Vicent Bodí & Juan Sanchis

  2. Servicio de Cardiología, Hospital de Manises, Valencia, Spain

    Gema Miñana

Authors
  1. Julio Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gema Miñana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francisco J. Chorro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vicent Bodí
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan Sanchis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julio Núñez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Núñez, J., Miñana, G., Núñez, E. et al. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail Rev 19, 575–584 (2014). https://doi.org/10.1007/s10741-013-9402-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-013-9402-y

Keywords

Search

Navigation